---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic impact on families"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic impact on families. Topics: Work productivity of care-partners and caregivers of patients with FSGS; Work productivity and financial well-being of 674 caregivers of patients with CKD in seven countries, including the United States; Loss of employer-sponsored health insurance after dialysis initiation in the United States; Direct and indirect costs to living kidney donors and their caregivers; 1 further topic. 5 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of APOL1-mediated kidney disease on Families

<a id="topic-2.2.1.8.3-1"></a>

### Work productivity of care-partners and caregivers of patients with FSGS

> “Additionally, 14–20% of care-partners and caregivers reported moderate to severe anxiety or depression. All employed groups reported high overall work impairment (15.0–30.6%), with adult patients and their care-partners reporting high FSGS-related activity impairment (37.8%; 17.3%, respectively), absenteeism (10.4%; 6.1%) and presenteeism (21.8%; 11.6%).”

Source: [Szklarzewicz et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12182477/)

<a id="topic-2.2.1.8.3-2"></a>

### Work productivity and financial well-being of 674 caregivers of patients with CKD in seven countries, including the United States

> “A total of 1303 patients and 674 caregivers were recruited.”
> “Work productivity and activity impairment were greatest among dialysis patients, a trend also observed among caregivers for patients on dialysis.”
> “Caregivers for patients with CKD generally reported a higher degree of impairment than the matched general population for absenteeism (mean range 3.4–14.7% vs. 1.4–20.8%; difference: − 7.6% to 12.0%), presenteeism (mean range 28.7–41.3% vs. 8.5–19.8%; difference: 12.0–28.2%), work activities (mean range 22.5–33.6% vs. 7.8–19.1%; difference: 11.1–23.7%), non-work activities (mean range 34.5–49.8% vs. 11.2–21.0%; difference: 17.9–34.9%).”
> “The indirect burden of CKD extends beyond clinical costs to include significant financial and work productivity impacts on patients and caregivers, with greater challenges for patients on dialysis.”

Source: [Chadban et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12909312/)

<a id="topic-2.2.1.8.3-3"></a>

### Loss of employer-sponsored health insurance after dialysis initiation in the United States

> “18,408 in-center hemodialysis and peritoneal dialysis patients employed full-time at the time of dialysis initiation, with employer-sponsored health insurance three months post-dialysis, followed for loss of employer-sponsored health insurance.”
> “Compared to patients receiving PD, patients receiving IHD without a fistula (HR, 1.26 [95% CI, 1.18–1.36]) and with a fistula (HR, 1.14 [95% CI, 1.05–1.24]) were more likely to lose employer-sponsored health insurance.”
> “Less than one quarter of working-age patients in the United States who began dialyzing between 1996 and 2013 were employed at dialysis initiation, and 38% of those employed six months prior to chronic dialysis were unemployed at dialysis start.”

Source: [Hirth et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094777/)

<a id="topic-2.2.1.8.3-4"></a>

### Direct and indirect costs to living kidney donors and their caregivers

> “We collected cost data in the 12 mo following donation from 182 LKDs participating in the multicenter prospective Kidney Donor Outcomes Cohort (KDOC) Study.”
> “LKDs missed 33 072 total work hours, 40% of which were unpaid and led to $302 175 in lost wages (mean $1660). Caregivers lost $68 655 in wages (mean $377). Although some donors received financial assistance, 89% had a net financial loss in the 12-mo period, with one-third (33%) reporting a loss exceeding $2500.”

Source: [Rodrigue et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26845630/)

<a id="topic-2.2.1.8.3-5"></a>

### Family implications of APOL1 genetic testing

> “Established guidance on disclosure of genetic test results to family members (cascade testing) should be followed. This typically involves provision of support and resources to a patient for passing on information to the family (if they choose) who may then seek counseling and testing.”
> “What are the impacts on individuals, families, and communities of donating and not donating kidneys from individuals with high-risk APOL1 genotypes (economic, psychological, societal), including consequences of continuing dialysis?”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Apolipoprotein L1 (APOL1) renal risk variants (RRVs) contribute to the increased risk of kidney disease among Black Americans, but use of genetic testing may be limited by patient concerns regarding clinical implications and effects on family.”

Source: [Elsurer Afsar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13438459/)

<a id="topic-2.2.1.8.3-6"></a>

### APOL1-specific family cost studies

No evidence found.

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
